AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23178932 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised mixed meal
Number of subjects: 37
Study 23178951 — intervention group
Group type: EXPERIMENTAL
Intervention: Amuvatinib dry powder capsules (DPC) 100 to 1,500 mg daily in 28-day cycles
Number of subjects: 22
Study 23178951 — intervention group
Group type: EXPERIMENTAL
Intervention: Amuvatinib dry powder capsules (DPC)
Number of subjects: 22
Study 23178977 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir/asunaprevir for 24 weeks
Number of subjects: 43
Study 23179335 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept 2.0 mg/kg with FOLFIRI
Number of subjects: 16
Study 23179335 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept 4.0 mg/kg with FOLFIRI
Number of subjects: 16
Study 23179562 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg ketorolac tromethamine (at delivery)
Number of subjects: 40
Study 23180114 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg once daily until disease progression or unacceptable toxicity
Number of subjects: 49
Study 23180239 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute hyperglycemia (PG 231.5 ± 18.1 mg/dl)
Number of subjects: 21
Study 23180239 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin resistance assessed by glucose infusion rate (GIR; mg/kg/min)
Number of subjects: 21
Study 23180507 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous/oral moxifloxacin (MXF, N = 110) 400 mg q.d.
Number of subjects: 206
Study 23180507 — intervention group
Group type: COMPARATOR
Intervention: Intravenous piperacillin/tazobactam 4.0/0.5 g t.d.s. followed by oral amoxicillin/clavulanate 875/125 mg b.d. (PIP/TAZ-AMC, N = 96)
Number of subjects: 206
Study 23182663 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 50mg p.o. daily for 4 weeks followed by 2 weeks off (6-week cycle)
Number of subjects: 24
Study 23182663 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 24
Study 23183434 — intervention group
Group type: EXPERIMENTAL
Intervention: PEGIFN/RBV
Number of subjects: 42
Study 23183434 — intervention group
Group type: EXPERIMENTAL
Intervention: PEGIFN AUC >0.79 mg · h/liter
Number of subjects: 42
Study 23183434 — intervention group
Group type: EXPERIMENTAL
Intervention: PEGIFN cumulative 1-week AUC ≤0.79 mg · h/liter
Number of subjects: 42
Study 23183437 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-9669
Number of subjects: 0
Study 23183526 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) and asunaprevir (ASV) for 24 weeks
Number of subjects: 43
Study 23184037 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV) in DNI patients
Number of subjects: 780
Study 23184037 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive ventilation (NIV) in patients with no TLD
Number of subjects: 780
Study 23184668 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxycarbamide (HC)
Number of subjects: 395
Study 23184668 — intervention group
Group type: EXPERIMENTAL
Intervention: Anagrelide
Number of subjects: 395
Study 23184668 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 395
Study 23185357 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest pulse pressure tertile
Number of subjects: 382
Study 23185357 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse pressure (PP)
Number of subjects: 382
Study 23185357 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip strength, body weight, age, history of diabetes mellitus
Number of subjects: 382
Study 23185357 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean arterial pressure, systolic BP, diastolic BP
Number of subjects: 382
Study 23185385 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 377
Study 23186837 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery with intra-abdominal oesophageal length measurement
Number of subjects: 34
Study 23186837 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery with Collis procedure if intra-abdominal oesophagus <1.5 cm
Number of subjects: 34
Study 23186915 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuron-specific enolase (NSE) increase
Number of subjects: 61
Study 23186915 — intervention group
Group type: EXPERIMENTAL
Intervention: New embolic events in DW-MRI
Number of subjects: 61
Study 23186915 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurological deficit assessed by NIHSS
Number of subjects: 61
Study 23186915 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma levels of NSE and new emboli in DW-MRI
Number of subjects: 61
Study 23186915 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sufficiency determined with established score systems (instrumental activities of daily living score, Barthel Index)
Number of subjects: 61
Study 23186915 — intervention group
Group type: EXPERIMENTAL
Intervention: All-cause mortality after 30 days and one year
Number of subjects: 61
Study 23186936 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment at discharge for patients with reduced LVEF included ACE inhibitors/ARBs (78%), beta-blockers (67%), and aldosterone inhibitors (27%).
Number of subjects: 1658
Study 23186936 — intervention group
Group type: EXPERIMENTAL
Intervention: Natriuretic peptide testing and echocardiography were performed in over 80% of patients.
Number of subjects: 1658
Study 23186936 — intervention group
Group type: EXPERIMENTAL
Intervention: Median hospital stay for patients was 13 days.
Number of subjects: 1658
Study 23187728 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-breathing radial DCE-MRI
Number of subjects: 14
Study 23187728 — intervention group
Group type: COMPARATOR
Intervention: Conventional VIBE images
Number of subjects: 14
Study 23187748 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET scans
Number of subjects: 121
Study 23187748 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scans
Number of subjects: 121
Study 23187748 — intervention group
Group type: COMPARATOR
Intervention: FDG-PET and CT scans
Number of subjects: 121
Study 23187897 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus plus octreotide LAR
Number of subjects: 44
Study 23187897 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus octreotide LAR
Number of subjects: 44
Study 23188784 — intervention group
Group type: EXPERIMENTAL
Intervention: Total thyroidectomy with central neck dissection (CND)
Number of subjects: 640
Study 23188784 — intervention group
Group type: COMPARATOR
Intervention: Total thyroidectomy without central neck dissection (CND)
Number of subjects: 640
Study 23189930 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal regular arrangement of collecting venules
Number of subjects: 617
Study 23189930 — intervention group
Group type: EXPERIMENTAL
Intervention: Type A (mosaic-like appearance)
Number of subjects: 617
Study 23189930 — intervention group
Group type: EXPERIMENTAL
Intervention: Type B (diffuse homogenous redness)
Number of subjects: 617
Study 23189930 — intervention group
Group type: EXPERIMENTAL
Intervention: Type C (untypical pattern)
Number of subjects: 617
Study 23189930 — intervention group
Group type: EXPERIMENTAL
Intervention: All abnormal patterns
Number of subjects: 617
Study 23190183 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-γ-1b (100 μg three times per week) added to PEG-IFN-α-2a (180 μg/week) and ribavirin (1000-1200 mg/day) for 32 weeks after initial 16 weeks of dual therapy.
Number of subjects: 48
Study 23190183 — intervention group
Group type: COMPARATOR
Intervention: PEG-IFN-α-2a (180 μg/week) and ribavirin (1000-1200 mg/day) for 16 weeks (initial dual therapy).
Number of subjects: 48
Study 23190221 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib (AP24534) administered once daily at doses ranging from 2 to 60 mg.
Number of subjects: 81
Study 23190385 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA)
Number of subjects: 10
Study 23190385 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac)
Number of subjects: 10
Study 23190385 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10
Study 23192220 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing + assessment feedback (EARLY)
Number of subjects: 217
Study 23192220 — intervention group
Group type: COMPARATOR
Intervention: Informational video
Number of subjects: 217
Study 23192220 — intervention group
Group type: COMPARATOR
Intervention: Informational brochure
Number of subjects: 217
Study 23193189 — intervention group
Group type: EXPERIMENTAL
Intervention: High physiological testosterone gel
Number of subjects: 12
Study 23193189 — intervention group
Group type: EXPERIMENTAL
Intervention: Low physiological testosterone gel
Number of subjects: 12
Study 23193189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 23193189 — intervention group
Group type: EXPERIMENTAL
Intervention: Castrate levels of testosterone (induced by gonadotropin-releasing hormone agonist treatment)
Number of subjects: 12
Study 23193207 — intervention group
Group type: EXPERIMENTAL
Intervention: hrA1C
Number of subjects: 3980
Study 23193207 — intervention group
Group type: EXPERIMENTAL
Intervention: IFG
Number of subjects: 3980
Study 23193207 — intervention group
Group type: COMPARATOR
Intervention: Comparison of hrA1C and IFG
Number of subjects: 3980
Study 23193944 — intervention group
Group type: EXPERIMENTAL
Intervention: Hereditary TTR amyloidosis
Number of subjects: 952
Study 23193944 — intervention group
Group type: EXPERIMENTAL
Intervention: Wild-type TTR amyloidosis
Number of subjects: 952
Study 23193944 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic carriers of disease-causing mutations
Number of subjects: 952
Study 23194056 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ASCT
Number of subjects: 167
Study 23194056 — intervention group
Group type: COMPARATOR
Intervention: Late ASCT
Number of subjects: 167
Study 23194193 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients achieving glycaemic goal (HbA(1c) <7%)
Number of subjects: 5817
Study 23194193 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients not achieving glycaemic goal (HbA(1c) ≥7%)
Number of subjects: 5817
Study 23194193 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with not achieving glycaemic goal
Number of subjects: 5817
Study 23194193 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivariate analyses factors associated with not achieving glycaemic goal
Number of subjects: 5817
Study 23194380 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium picolinate 500 μg twice a day
Number of subjects: 31
Study 23194380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 23194380 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium picolinate
Number of subjects: 31
Study 23194380 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium therapy
Number of subjects: 31
Study 23194482 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction rules developed from prospectively gathered evaluation and treatment data in the acute setting (STRATIFY) and early inpatient stay (DECIDE)
Number of subjects: 0
Study 23194482 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive cardiology review for assigning post-treatment outcomes
Number of subjects: 0
Study 23194482 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigorous analysis plan for constructing prediction rules
Number of subjects: 0
Study 23194494 — intervention group
Group type: EXPERIMENTAL
Intervention: Framingham equation including traditional risk factors
Number of subjects: 19811
Study 23194494 — intervention group
Group type: COMPARATOR
Intervention: Framingham equation including traditional risk factors plus CKD and race
Number of subjects: 19811
Study 23194494 — intervention group
Group type: COMPARATOR
Intervention: ALLHAT model including CKD and race
Number of subjects: 19811
Study 23194775 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital delirium
Number of subjects: 53
Study 23194775 — intervention group
Group type: COMPARATOR
Intervention: No in-hospital delirium
Number of subjects: 53
Study 23195326 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with epinephrine (1:200,000)
Number of subjects: 0
Study 23196037 — intervention group
Group type: EXPERIMENTAL
Intervention: Parkinson's disease patients
Number of subjects: 80
Study 23196037 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 80
Study 23196955 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantiferon-CMV assay (measuring interferon-γ levels)
Number of subjects: 127
Study 23196955 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantiferon-CMV positive result
Number of subjects: 127
Study 23196955 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantiferon-CMV negative result
Number of subjects: 127
Study 23196955 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantiferon-CMV indeterminate result
Number of subjects: 127
Study 23196955 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantiferon-CMV assay
Number of subjects: 127
Study 23197081 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib (45 mg single dose followed by 30 mg continuous once-daily for 21 days)
Number of subjects: 30
Study 23197081 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib (30 mg continuous once-daily dosing)
Number of subjects: 30
Study 23197081 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib
Number of subjects: 30
Study 23197234 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib treatment
Number of subjects: 17
Study 23197288 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton-pump inhibitor (PPI) treatment
Number of subjects: 0
Study 23197288 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 23197414 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine trial with skin biopsy leaving a 6-cm scar
Number of subjects: 91
Study 23197414 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine trials requiring skin biopsy leaving a 3-cm scar
Number of subjects: 91
Study 23197414 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine trials requiring skin biopsy leaving a 6-cm scar
Number of subjects: 91
Study 23197414 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine trials requiring skin biopsy leaving a 12-cm scar
Number of subjects: 91
Study 23197414 — intervention group
Group type: COMPARATOR
Intervention: Vaccine trials without biopsy
Number of subjects: 91
Study 23197589 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraventricular rituximab (10 mg or 25 mg) administered twice weekly for 4 weeks, with rituximab as monotherapy during the first treatment each week and in combination with methotrexate (MTX) during the second treatment each week.
Number of subjects: 14
Study 23197589 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraventricular rituximab/MTX
Number of subjects: 14
Study 23199229 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone 75 mg (protocol 2)
Number of subjects: 42
Study 23199229 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone 7.5 mg, 15 mg, 30 mg (protocol 1)
Number of subjects: 42
Study 23199229 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone (all doses)
Number of subjects: 42
Study 23199555 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-proADM
Number of subjects: 1179
Study 23199555 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-proADM + hs-cTnT
Number of subjects: 1179
Study 23199555 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-proADM + TIMI-score
Number of subjects: 1179
Study 23199641 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity meeting weekly recommendations
Number of subjects: 305
Study 23199641 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived benefits of exercise
Number of subjects: 305
Study 23199641 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived barriers to exercise
Number of subjects: 305
Study 23199641 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse prevention as a benefit of exercise
Number of subjects: 305
Study 23199894 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxycarbamide (HC)
Number of subjects: 3643
Study 23199894 — intervention group
Group type: EXPERIMENTAL
Intervention: Anagrelide
Number of subjects: 3643
Study 23199894 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-aggregatory therapy
Number of subjects: 3643
Study 23199894 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive treatment patterns
Number of subjects: 3643
Study 23200268 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity warfarin therapy
Number of subjects: 0
Study 23200980 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of mutant TP53 in duodenal samples of secretin-stimulated pancreatic juice from patients with pancreatic ductal adenocarcinoma.
Number of subjects: 180
Study 23200980 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of mutant TP53 in duodenal samples of secretin-stimulated pancreatic juice from patients with high-grade lesions (PanIN-3 and high-grade IPMN).
Number of subjects: 180
Study 23200980 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of mutant TP53 in duodenal samples of secretin-stimulated pancreatic juice from patients with intermediate-grade IPMNs.
Number of subjects: 180
Study 23200980 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of mutant TP53 in duodenal samples of secretin-stimulated pancreatic juice from patients with PanIN-2 lesions.
Number of subjects: 180
Study 23200980 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of mutant TP53 in duodenal samples of secretin-stimulated pancreatic juice from patients with high-grade IPMNs.
Number of subjects: 180
Study 23200980 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of mutant TP53 in duodenal samples of secretin-stimulated pancreatic juice from patients with PanIN-3 lesions.
Number of subjects: 180
Study 23200980 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of mutant TP53 in duodenal samples of secretin-stimulated pancreatic juice from patients with invasive pancreatic adenocarcinomas.
Number of subjects: 180
Study 23200980 — intervention group
Group type: COMPARATOR
Intervention: Detection of mutant TP53 in duodenal samples of secretin-stimulated pancreatic juice from controls.
Number of subjects: 180
Study 23201699 — intervention group
Group type: EXPERIMENTAL
Intervention: High β-palmitate formula (HBP group, n=14)
Number of subjects: 36
Study 23201699 — intervention group
Group type: COMPARATOR
Intervention: Low β-palmitate formula (LBP group, n=8)
Number of subjects: 36
Study 23201699 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-fed (BF group, n=14)
Number of subjects: 36
Study 23201707 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil-based lipid emulsions (FOE)
Number of subjects: 6
Study 23204083 — intervention group
Group type: EXPERIMENTAL
Intervention: Placement of resin-based composite restorations
Number of subjects: 172
Study 23204247 — intervention group
Group type: EXPERIMENTAL
Intervention: Microaneurysm (MA) turnover calculated using RetmarkerDR
Number of subjects: 410
Study 23204247 — intervention group
Group type: EXPERIMENTAL
Intervention: Microaneurysm (MA) turnover predictive values
Number of subjects: 410
Study 23205612 — intervention group
Group type: EXPERIMENTAL
Intervention: SRT501 (resveratrol) with bortezomib
Number of subjects: 0
Study 23205612 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 23207683 — intervention group
Group type: EXPERIMENTAL
Intervention: Image-guided robotic surgery using preoperative CT-angiography
Number of subjects: 12
Study 23207876 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (0.44-2.23 mg/kg/day)
Number of subjects: 27
Study 23207876 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (0.07-0.72 mg/kg/day)
Number of subjects: 27
Study 23207876 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 27
Study 23208080 — intervention group
Group type: EXPERIMENTAL
Intervention: RV automated systolic index (RV-ASI) obtained from semi-automated border detection using 2D echocardiography
Number of subjects: 40
Study 23208080 — intervention group
Group type: EXPERIMENTAL
Intervention: RV-ASI cut-off value of 52 %
Number of subjects: 40
Study 23208080 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-observer variability
Number of subjects: 40
Study 23208080 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-observer variability
Number of subjects: 40
Study 23208833 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir 150 mg administered nasogastrically or nasoenterically every 12 hours
Number of subjects: 13
Study 23208833 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir carboxylate
Number of subjects: 13
Study 23208833 — intervention group
Group type: COMPARATOR
Intervention: Patients receiving ECMO
Number of subjects: 13
Study 23209861 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifurtimox-eflornithine combination therapy (NECT)
Number of subjects: 629
Study 23210427 — intervention group
Group type: EXPERIMENTAL
Intervention: Five gene predictive model (CLDND1, LRRN3, MUC1, GOPC, LEF1)
Number of subjects: 209
Study 23210427 — intervention group
Group type: EXPERIMENTAL
Intervention: Five gene predictive model
Number of subjects: 209
Study 23210427 — intervention group
Group type: COMPARATOR
Intervention: Cotinine model (threshold of 10 ng/ml)
Number of subjects: 209
Study 23210876 — intervention group
Group type: EXPERIMENTAL
Intervention: Misago self-expanding nitinol stent
Number of subjects: 744
Study 23211576 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 477
Study 23211708 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratendinous leukocyte-rich PRP injection
Number of subjects: 25
Study 23211938 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ridaforolimus (40 mg QD × 5 days/week)
Number of subjects: 147
Study 23212516 — intervention group
Group type: EXPERIMENTAL
Intervention: Hu-Mikβ1 (humanized mAb directed at IL-2/IL-15Rβ subunit, CD122)
Number of subjects: 0
Study 23212516 — intervention group
Group type: COMPARATOR
Intervention: Previous murine Mikβ1
Number of subjects: 0
Study 23212718 — intervention group
Group type: EXPERIMENTAL
Intervention: 325-mg immediate release aspirin
Number of subjects: 400
Study 23212718 — intervention group
Group type: EXPERIMENTAL
Intervention: 325-mg enteric coated aspirin
Number of subjects: 400
Study 23212718 — intervention group
Group type: EXPERIMENTAL
Intervention: 81 mg low-dose enteric coated aspirin
Number of subjects: 400